Core Viewpoint - Jiuzhou Pharmaceutical has seen a significant stock price increase, with a 5.31% rise on November 14, reaching 21.42 yuan per share, and a total market capitalization of 19.052 billion yuan, indicating strong investor interest and performance in the market [1]. Company Overview - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1]. - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1]. Shareholder Insights - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund has increased its holdings. The China Europe Medical Health Mixed A Fund (003095) added 3.9767 million shares in the third quarter, bringing its total to 17.403 million shares, which represents 1.96% of the circulating shares [2]. - The fund has realized a floating profit of approximately 18.7952 million yuan today, with a total floating profit of 15.8367 million yuan during the four-day stock price increase [2]. Fund Manager Performance - The fund manager of China Europe Medical Health Mixed A, Ge Lan, has a tenure of 10 years and 293 days, with a total fund size of 43.544 billion yuan. The best return during her tenure is 109.26%, while the worst is -35.13% [3]. - Co-manager Zhao Lei has been in position for 134 days, managing a fund size of 32.954 billion yuan, with a best return of 8.82% and a worst return of 8.51% during his tenure [3].

Core Points - The ownership structure of Jiuzhou Pharmaceutical has changed, with Huaxuande no longer holding shares in Zhongbei Group and Taizhou Gede, leading to a new actual controller structure involving Huali Rong and Huaxiao Hui [2][3] - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4] Group 1 - Huaxuande transferred 28.50% of Zhongbei Group's shares to Huali Rong and 14% to Huaxiao Hui, with total payments amounting to 61.815 million yuan [2] - Following the transfer, Huali Rong holds 22.17% and Huaxiao Hui holds 13.36% of Jiuzhou Pharmaceutical indirectly [2] - The market value of Jiuzhou Pharmaceutical shares held by Zhongbei Group and Taizhou Gede is estimated at approximately 24.76 billion yuan [2] Group 2 - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [3] - Huaxuande, aged 82, stepped down as chairman in 2014, with his daughter Huali Rong succeeding him [3] - Huali Rong has held various leadership roles and was recently elected as the executive director and legal representative of Jiuzhou Pharmaceutical [3] Group 3 - Huaxuande and his family's wealth was ranked 338th on the Hurun Rich List in 2020 with 16 billion yuan, and they are currently ranked 2750th and 940th on the global and national rich lists, respectively [4] - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [4]

Core Viewpoint - The control of Jiuzhou Pharmaceutical has changed due to the transfer of shares from the aging actual controller, Hua Xuande, to his daughters, Hua Lirong and Hua Xiaohui, which will not affect the company's operational independence or business performance [2][4]. Group 1: Share Transfer Details - Hua Xuande transferred 42.50% of his shares in Zhongbei Group and 10.00% in Taizhou Gede to his daughters, with Hua Lirong receiving 28.50% and Hua Xiaohui 14% of Zhongbei Group, and each receiving 5% of Taizhou Gede [1]. - The total payment for the share transfer was 61.815 million yuan, with Hua Lirong paying 41.333 million yuan and Hua Xiaohui 20.482 million yuan [1]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's closing price of 19.88 yuan per share, is approximately 2.476 billion yuan [1]. Group 2: Company Background and Performance - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [4]. - The company reported a revenue of 4.16 billion yuan for the first three quarters of the year, representing a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4]. - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [5].

Core Viewpoint - The article discusses the transfer of significant equity stakes in Zhongbei Group and Taizhou Gede by Huaxuande, an 82-year-old billionaire, to his daughters, marking his intention to retire from active involvement in the companies [1]. Group 1: Equity Transfer Details - Huaxuande plans to transfer 42.50% of his stake in Zhongbei Group and 10% in Taizhou Gede to his daughters, with 28.50% going to Huayi Rong and 14% to Huayi Hui [1]. - The daughters will pay 41.33 million yuan and 20.48 million yuan for their respective stakes [1]. - Following the transfer, Huaxuande will no longer hold any shares in Zhongbei Group or Taizhou Gede, nor will he indirectly hold shares in the listed company [1]. Group 2: Market Valuation - Zhongbei Group and Taizhou Gede hold approximately 283.52 million shares and 40.58 million shares of Jiuzhou Pharmaceutical, respectively [2]. - Based on Jiuzhou Pharmaceutical's closing price of 19.88 yuan per share as of November 11, the market value of these shares is estimated at 5.636 billion yuan and 807 million yuan [2]. - The total market value of the shares indirectly held by Huaxuande through the transferred stakes is approximately 2.476 billion yuan [2].

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical has changed as Huaxuande transfers his shares to his daughters, resulting in a shift in control to them due to Huaxuande's advanced age [1][9]. Shareholding Structure - Huaxuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, with Huaxuande no longer holding any shares post-transfer [3][9]. - After the transfer, Huaxuande's daughters hold 22.17% and 13.36% of Jiuzhou Pharmaceutical, respectively, while Huaxuande exits the role of actual controller [1][9]. Financial Details - The total consideration for the share transfer was approximately 61.115 million yuan for Zhongbei Group and 700,000 yuan for Taizhou Gede [9]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's stock price of 20.23 yuan per share, is approximately 2.5191 billion yuan [7][9]. Background Information - Huaxuande, born in 1943, is the founder of Jiuzhou Pharmaceutical and has gradually stepped back from management roles due to age, having resigned from key positions since 2017 [11][12]. - Jiuzhou Pharmaceutical transitioned from producing chemical raw materials to contract custom development and production since 2008, and it was listed on the Shanghai Stock Exchange in 2014 [11].

Group 1 - The board of directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. held its 18th meeting of the 8th session on November 12, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the election of Ms. Hua Lirong as the representative director to execute company affairs and as the legal representative, with her term lasting until the end of the current board's term [3][4] - The board also approved the election of members for the audit committee, including Ms. Jiang Qi, Mr. Yang Lirong, and Mr. Li Jicheng, with Ms. Jiang serving as the committee's convener [5][6] Group 2 - The audit committee is composed of a majority of independent directors, complying with relevant laws and regulations [5] - The term for the newly elected audit committee members will also last until the end of the current board's term [5]

Group 1 - The company announced the convening of the eighth employee representative assembly on November 12, 2025 [2] - During the assembly, employees voted to remove Mr. Chen Jinkang from his position as employee supervisor [2] - Ms. Chen Liyue was elected as the employee representative director for the company's eighth board of directors [2]

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical, Hua Xuande, has transferred his shares to his daughters, resulting in a change in the company's control structure, primarily due to Hua's advanced age [2][3][4]. Share Transfer Details - Hua Xuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, Hua Lirong and Hua Xiaohui [3][4]. - After the transfer, Hua Lirong holds 22.17% of Jiuzhou Pharmaceutical directly and indirectly, while Hua Xiaohui holds 13.36% indirectly [2][3]. Financial Aspects - The total value of the shares transferred from Zhongbei Group was 61.115 million yuan, and the shares from Taizhou Gede were valued at 700,000 yuan [4]. Background Information - Hua Xuande, born in 1943, is 82 years old and has gradually stepped back from management roles in Jiuzhou Pharmaceutical over recent years [5][9]. - The company was founded focusing on the research, production, and sales of chemical raw materials and pharmaceutical intermediates, later transitioning to contract custom development and production [9]. Control Structure Post-Transfer - Following the transfer, the actual controllers of Jiuzhou Pharmaceutical are now Hua Lirong and Hua Xiaohui, with Zhongbei Group remaining the controlling shareholder [4][8].

Core Points - The company announced the convening of the 18th meeting of the 8th Board of Directors on November 12, 2025 [1] - During the meeting, Hua Lirong was elected as the director representing the company to execute company affairs [1] - Hua Lirong will also serve as the legal representative of the company, with a term lasting until the end of the current Board's term [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-066 二、选举职工代表董事情况 根据《中华人民共和国公司法》及《公司章程》等相关规定，公司于 2025 年 11 月 12 日召开第八届职工代表大会，经与会职工讨论并投票表决，同意免去 陈锦康先生的职工监事职务，并选举陈丽月女士（简历附后）为公司第八届董事 会职工代表董事，任期自本次公司职工代表大会选举通过之日起至公司第八届董 事会任期届满之日止。 陈丽月女士符合相关法律法规、规范性文件及《公司章程》有关董事任职的 资格和条件。本次选举职工代表董事工作完成后，公司第八届董事会中兼任公司 高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二分 之一。 浙江九洲药业股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、非独立董事辞职情况 浙江九洲药业股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事 LI YUANQIANG 先生的辞职报告，因公司治理结构调整，LI YUANQIANG ...